These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23410161)

  • 1. Rationally designed multi-targeted agents against neurodegenerative diseases.
    Geldenhuys WJ; Van der Schyf CJ
    Curr Med Chem; 2013; 20(13):1662-72. PubMed ID: 23410161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases.
    Van der Schyf CJ; Gal S; Geldenhuys WJ; Youdim MB
    Expert Opin Investig Drugs; 2006 Aug; 15(8):873-86. PubMed ID: 16859391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases.
    Pisani L; Catto M; Leonetti F; Nicolotti O; Stefanachi A; Campagna F; Carotti A
    Curr Med Chem; 2011; 18(30):4568-87. PubMed ID: 21864289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
    Zindo FT; Barber QR; Joubert J; Bergh JJ; Petzer JP; Malan SF
    Eur J Med Chem; 2014 Jun; 80():122-34. PubMed ID: 24769350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
    Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
    Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.
    Mathew B; Parambi DGT; Mathew GE; Uddin MS; Inasu ST; Kim H; Marathakam A; Unnikrishnan MK; Carradori S
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900177. PubMed ID: 31478569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and pharmacological evaluation of 2-amino-5-nitrothiazole derived semicarbazones as dual inhibitors of monoamine oxidase and cholinesterase: effect of the size of aryl binding site.
    Tripathi RKP; M Sasi V; Gupta SK; Krishnamurthy S; Ayyannan SR
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):37-57. PubMed ID: 29098902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Searching for Multi-Targeting Neurotherapeutics against Alzheimer's: Discovery of Potent AChE-MAO B Inhibitors through the Decoration of the 2H-Chromen-2-one Structural Motif.
    Pisani L; Farina R; Soto-Otero R; Denora N; Mangiatordi GF; Nicolotti O; Mendez-Alvarez E; Altomare CD; Catto M; Carotti A
    Molecules; 2016 Mar; 21(3):362. PubMed ID: 26999091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
    Koch P; Akkari R; Brunschweiger A; Borrmann T; Schlenk M; Küppers P; Köse M; Radjainia H; Hockemeyer J; Drabczyńska A; Kieć-Kononowicz K; Müller CE
    Bioorg Med Chem; 2013 Dec; 21(23):7435-52. PubMed ID: 24139167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indole alkaloids and semisynthetic indole derivatives as multifunctional scaffolds aiming the inhibition of enzymes related to neurodegenerative diseases--a focus on Psychotria L. Genus.
    Klein LC; Passos CS; Moraes AP; Wakui VG; Konrath EL; Nurisso A; Carrupt PA; de Oliveira CM; Kato L; Henriques AT
    Curr Top Med Chem; 2014; 14(8):1056-75. PubMed ID: 24660679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.
    Ramsay RR; Tipton KF
    Molecules; 2017 Jul; 22(7):. PubMed ID: 28714881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computer Aided Drug Design Studies in the Discovery of Secondary Metabolites Targeted Against Age-Related Neurodegenerative Diseases.
    Scotti L; Scotti MT
    Curr Top Med Chem; 2015; 15(21):2239-52. PubMed ID: 26059353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.
    Zindo FT; Joubert J; Malan SF
    Future Med Chem; 2015; 7(5):609-29. PubMed ID: 25921401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinolinic Carboxylic Acid Derivatives as Potential Multi-target Compounds for Neurodegeneration: Monoamine Oxidase and Cholinesterase Inhibition.
    Khan NA; Khan I; Abid SMA; Zaib S; Ibrar A; Andleeb H; Hameed S; Iqbal J
    Med Chem; 2018; 14(1):74-85. PubMed ID: 28545383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
    Lan JS; Ding Y; Liu Y; Kang P; Hou JW; Zhang XY; Xie SS; Zhang T
    Eur J Med Chem; 2017 Oct; 139():48-59. PubMed ID: 28797883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
    Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
    J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.